by Jennifer Couzin-Frankel

Slides:

Advertisements

Similar presentations

Carcinogen - an agent known to cause cancer.

Advertisements

Waging War on Cancer with the Sword of Immunity Cell Volume 158, Issue 2, (July 2014) DOI: /j.cell Copyright © 2014 Terms and Conditions.

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings PowerPoint® Lectures Lectures by April Lynch Tumor-Busting Viruses Current Issues.

Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings PowerPoint® Lectures for Biology: Concepts and Connections, Fifth Edition – Campbell,

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

The Good Fat Cell Volume 147, Issue 7, (December 2011) DOI: /j.cell Copyright © 2011 Terms and Conditions Terms and Conditions.

Progress in Cancer Therapy Following Developments in Biopharma

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Volume 164, Issue 6, Pages (December 2000)

Biologic Medicines.

209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.

Immunotherapy of hepatocellular carcinoma

Chapter 08 The T Cell Receptor: Proteins and Genes

by Jennifer Couzin-Frankel

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies Jose R. Conejo-Garcia, Melanie R. Rutkowski

Inhibitor of MAP kinase activation blocks colon cancer growth

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

Advances in food allergy in 2015

Advances in Specific Immunotherapy for Prostate Cancer

Volume 199, Issue 1, (January 2018)

Engineering Natural Killer Cells for Cancer Immunotherapy

Advances in the Treatment of Metastatic Prostate Cancer

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Multiple Effects of Angiopoietin-2 Blockade on Tumors

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

The Immune System Second Edition

Daniel Abate-Daga, Marco L Davila Molecular Therapy - Oncolytics

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Engineering Natural Killer Cells for Cancer Immunotherapy

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Volume 26, Issue 6, Pages (December 2014)

Targeting T Cell Co-receptors for Cancer Therapy

Mechanisms of LtxA (Leukotoxin), a Potent New Anti-Inflammatory Agent for the Treatment of Alopecia Areata Scott C. Kachlany Journal of Investigative.

Cancer Evolution Constrained by the Immune Microenvironment

Volume 132, Issue 6, Pages (December 2007)

Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Volume 143, Issue 6, (December 2010)

Multiple Effects of Angiopoietin-2 Blockade on Tumors

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R

Statistical Issues in Longitudinal Data Analysis for Treatment Efficacy Studies in the Biomedical Sciences Chunyan Liu, Timothy P Cripe, Mi-Ok Kim Molecular.

Chimeric antigen receptor T-cell therapy for solid tumors

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Cancer Treatment.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

The discovery of IgE Journal of Allergy and Clinical Immunology

NCMs regulate T cell survival in TLOs via PD-L1.

by Jennifer Couzin-Frankel

Releasing the Brakes on Cancer Immunotherapy

Toxicity and management in CAR T-cell therapy

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Padmanee Sharma, James P. Allison Cell

BMS blocks functional responses in primary immune cells driven by IFNα

Natural processing and presentation of the HOM-MEL-40/SSX2-derived p peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

Normalizing the tumor microenvironment

CAR T cell immunotherapy for human cancer

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

by Jennifer Couzin-Frankel Cancer Immunotherapy by Jennifer Couzin-Frankel Science Volume 342(6165):1432-1433 December 20, 2013 Copyright © 2013, American Association for the Advancement of Science

Domino effect. Domino effect. One such treatment, with the antibody in pink at the top, works by blocking a protein receptor, in purple, on a T cell. That sets off a chain reaction that allows T cells to target a tumor cell (bottom left). Jennifer Couzin-Frankel Science 2013;342:1432-1433 Copyright © 2013, American Association for the Advancement of Science

Arsenal.New antibody therapies, depicted here, are stimulating the immune system to destroy cancer cells. Arsenal.New antibody therapies, depicted here, are stimulating the immune system to destroy cancer cells. Jennifer Couzin-Frankel Science 2013;342:1432-1433 Copyright © 2013, American Association for the Advancement of Science